Bacterial Infections  >>  ribaxamase (SYN-004)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ribaxamase (SYN-004) / Theriva Bio
NCT02563106 / 2015-002346-32: A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Completed
2
413
Canada, US, Europe, RoW
SYN-004, Placebo
Synthetic Biologics Inc.
Clostridium Difficile, Clostridium Infections
11/16
11/16

Download Options